Dozens of executives of pharmaceutical companies have left this year, and traditional Chinese medicine companies account for the majority

Recently, China Resources Sanjiu announced that the board of directors of the company received the resignation report submitted by directors Mr.
Han Yuewei and Mr.
Wei Xing on February 18, 2022.
Due to job changes, Han Yuewei proposed to resign as a director of the eighth board of directors of the company, and Wei Xing proposed He resigned as a director of the 8th Board of Directors and a member of the Remuneration and Appraisal Committee of the Board of Directors
.
No longer hold positions in the company after resignation
.
Coincidentally, on the same day, the board of directors of Buchang Pharmaceutical also received a written resignation report submitted by the company's director and vice president Li Weijun
.
According to the report, Li Weijun applied to resign as the company's director, vice president and member of the compensation and appraisal committee of the board of directors due to personal reasons, and at the same time resigned from all positions held in the company's subsidiaries
.
After his resignation from the above-mentioned positions, he will not hold any positions in the company
.
In fact, the changes of executives of pharmaceutical companies are already very common
.
This year, many senior executives of domestic pharmaceutical companies have chosen to leave the industry temporarily
.
According to statistics, from January 1 to February 24, 2022, a total of 68 resignations have occurred in listed pharmaceutical companies, and 28 company executives have temporarily left or left the pharmaceutical industry
.
Among them, traditional Chinese medicine companies account for a large proportion, and 19 companies are involved in resignation, followed by chemical pharmaceutical companies, and 6 companies have resigned
.
On the whole, most executives in the pharmaceutical industry resigned on the grounds of "personal reasons"
.
In this regard, the industry believes that, from a deep perspective, the resignation of executives is still related to the current environment of the pharmaceutical industry, especially under the pressure of centralized procurement and performance growth, most executives are facing huge performance pressures.
Choose to leave
.
According to public information, at the State Council's policy briefing held on February 11 this year, the National Medical Insurance Bureau stated that the centralized procurement will continue to expand on the basis of normalization and institutionalization
.
In the future, medicines will be developed in three major sectors: chemical medicines, proprietary Chinese medicines and biological medicines.
High-value medical consumables will focus on orthopedic consumables, drug balloons, dental implants and other varieties.
By the end of 2022, they will be purchased through national organizations and provincial alliances.
Achieve an average coverage of more than 350 drug varieties per province, and more than 5 varieties of high-value medical consumables
.
In this context, a large number of medicines and consumables will be greatly reduced in price after centralized procurement, so that citizens can enjoy more benefits
.
But at the same time, for the centralized procurement companies, their performance growth will also be under more pressure
.
Under these pressures, more changes are expected in related companies and a large number of executives
.
In fact, in addition to domestic pharmaceutical companies, multinational pharmaceutical companies face major changes in the domestic pharmaceutical market, and their executives change very frequently, and personnel changes are often accompanied by business structure adjustments
.
It is reported that on January 20, the relevant person in charge of AstraZeneca announced to employees that from March 1, 2022, Chen Kangwei, the current general manager of AstraZeneca China Taiwan, will be appointed as the general manager of AstraZeneca China Oncology Division.
Responsible for AstraZeneca's oncology business in China
.
In addition, in January, Pfizer also announced the general managers and heads of other divisions of the six independent divisions except rare diseases and broad markets
.
It is understood that this personnel adjustment is a follow-up to the previous restructuring of Pfizer
.
In September 2021, Pfizer announced that the structure of China will be adjusted to establish 6 independent business units, including hospital emergency, oncology, rare diseases, inflammation and immunity, vaccines, and broad market
.
From the above point of view, behind the frequent changes of senior executives of pharmaceutical companies, it is mainly one of the responses made by pharmaceutical companies in response to the changes in the pattern of the pharmaceutical industry
.
In the future, with the continuous changes in the pharmaceutical industry, it is expected that the changes of executives of pharmaceutical companies will only become more frequent
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.